BEVERLY, MA--(Marketwire - February 04, 2010) - INVO Bioscience, Inc. (OTCBB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announces the birth of the first INVO baby in Venezuela. The baby boy was born on January 31, 2010 to a 46-year-old woman who had been treated at the CEVALFES Center for Fertility in Valencia. The mother Yolima Nelo said, “I am very happy and send many kisses to Claude (Dr. Ranoux) for this great result.” The mother and new baby boy Rodolfo Francisco are doing well. Dr. Antonia Sonoja, the physician who performed this INVO procedure, was one of the key note speakers at the Salvador Society of Endoscopy and Reproduction Symposium on January 30th where INVO was presented to over 100 doctors from Central and South America.
About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company’s main product, the INVOcell, is a novel medical device used in an infertility treatment that enables egg fertilization and early embryo development in the woman’s vaginal cavity. The woman’s body acts as a natural incubator making it a much more personal experience. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Kathleen Karloff
INVO Bioscience, Inc.
978-878-9505 x505
www.invobioscience.com
